Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report by State

Kidney & Renal Pelvis (Late Stage^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Count

Explanation of Column Headers
Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Percent of Cases with Late Stage - This is the number of late stages cases compared to the number of cases for all stages.


Other Notes


Line by Line Interpretation of the Report


US (SEER+NPCR)1


District of Columbia2


Wyoming2


Alaska2


Vermont2


North Dakota2


Delaware2


South Dakota2


Montana2


Rhode Island2


Hawaii7


New Hampshire2


Puerto Rico2


Maine2


Idaho7


Utah7


Nebraska2


Nevada2


New Mexico7


West Virginia2


Kansas2


Mississippi2


Arkansas2


Connecticut7


Oregon2


Colorado2


Iowa7


Alabama2


Oklahoma2


Maryland2


South Carolina2


Kentucky7


Louisiana7


Minnesota2


Massachusetts2


Arizona2


Wisconsin2


Virginia2


Washington1


Missouri2


Tennessee2


Indiana2


New Jersey7


Georgia7


Michigan2


North Carolina2


Pennsylvania2


Ohio2


Illinois7


New York7


Florida2


Texas7


California7





Notes:
Created by statecancerprofiles.cancer.gov on 03/23/2026 10:42 am.

State Cancer Registries may provide more current or more local data.

Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.


† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2024 submission.

2 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2024 submission).

7 Source: SEER November 2024 submission.

Data for United States does not include Puerto Rico.